What is Nektar Therapeutics (NKTR) stock price today?

Nektar Therapeutics (NKTR) currently trades at $83.20 per share. The stock has a market capitalization of $2.76B and a P/E ratio of —x.

Is NKTR stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Nektar Therapeutics has a Smart Value Score of 28/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -16.87.

What is Nektar Therapeutics's revenue and earnings?

Nektar Therapeutics has trailing twelve-month (TTM) revenue of $55.23M with profit margins of -297.10%. Earnings per share (EPS) is $-9.73.

Is Nektar Therapeutics financially healthy?

Nektar Therapeutics's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -16.87 places it in the distress.

NKTR

Nektar Therapeutics

NASDAQ: NKTR · HEALTHCARE · BIOTECHNOLOGY

$83.20

-0.73% today

Updated 2026-04-29

Market cap

$2.76B

P/E ratio

—

P/S ratio

50.03x

EPS (TTM)

$-9.73

Dividend yield

—

52W range

$8 – $109

Volume

1.1M

Market cap

$2.76B

P/E ratio

—

P/S ratio

50.03x

EPS (TTM)

$-9.73

Dividend yield

—

52W range

$8 – $109

Volume

1.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

5.3

Quality

C+

2.0

Profitability

6.7

Valuation

2/9

Piotroski F-Score

Weak

-16.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$144.25

+73.38%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy8 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -16.87 — distress zone

- Thin margins at -297.10%

- Negative free cash flow $-64.98M

- Revenue declining -25.30% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$92.06M	$90.12M	$98.43M	$55.23M	$55.23M
Net income	$-368.20M	$-276.06M	$-118.96M	$-164.08M	$-36.08M
EPS	—	—	—	—	$-9.73
Free cash flow	$-309.68M	$-193.47M	$-177.18M	$-208.68M	$-64.98M
Profit margin	-399.98%	-306.31%	-120.86%	-297.07%	-297.10%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NKTR	$2.76B	28	2.7	2.0	6.7	5.3	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Nektar Therapeutics trades at $83.20. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -16.87, it sits in the distress. TTM revenue stands at $55.23M. with profit margins at -297.10%.

Frequently asked questions

What is Nektar Therapeutics's stock price?

Nektar Therapeutics (NKTR) trades at $83.20.

Is Nektar Therapeutics overvalued?

Smart Value Score 28/100 (Grade F, Strong Sell).

What is the price target of Nektar Therapeutics (NKTR)?

The analyst target price is $144.25, representing +73.4% upside from the current price of $83.20.

What is Nektar Therapeutics's revenue?

TTM revenue is $55.23M.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-16.87 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio50.03x

ROE-217.90%

Beta1.18

50D MA$76.34

200D MA$53.15

Shares out0.03B

Float0.03B

Short ratio—

Avg volume1.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

NKTR vs LLY →NKTR vs JNJ →NKTR vs ABBV →Stock screener →